Influence of imperatorin on the anticonvulsant activity and acute adverse-effect profile of lamotrigine in maximal electroshock-induced seizures and chimney test in mice

Pharmacological Reports

Volumn 60, Issue 4, 2008, Pages 566-573

  Łuszczki, Jarogniew J ^a,b   Wojda, Ewa ^a   Raszewski, Grzegorz ^b   Głowniak, Kazimierz ^a   Czuczwar, Stanisław J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Chimney test; Imperatorin; Lamotrigine; Maximal electroshock seizure test; Protective index

Indexed keywords

LAMOTRIGINE; PENTOSALEN;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG POTENTIATION; DRUG RESPONSE; ELECTRIC SHOCK; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; SEIZURE;

EID: 52049086250     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Baek NI, Ahn EM, Kim HY, Park YD: Furanocoumarins from the root of Angelica dahurica. Arch Pharm Res, 2000, 23, 467-470.
2. Bergendorff O, Dekermendjian K, Nielsen M, Shan R, Witt R, Ai J, Sterner O: Furanocoumarins with affinity to brain benzodiazepine receptors in vitro. Phytochemistry, 1997, 44, 1121-1124.
3. Binnie CD, de Beukelaar F, Meijer JW, Meinardi H, Overweg J, Wauquier A, van Wieringen A: Open dose-ranging trial of flunarizine as add-on therapy in epilepsy. Epilepsia, 1985, 26, 424-428.
4. Boissier JR, Tardy J, Diverres JC: A new simple method to explore the tranquilizing action: a chimney test (in French). Med Exp (Basel), 1960, 3, 81-84.
5. Brodie MJ, Schachter SC: Fast Facts. Epilepsy, 2nd edn., Health Press, Oxford, 2001.
6. Choi SY, Ahn EM, Song MC, Kim DW, Kang JH, Kwon OS, Kang TC, Baek NI: In vitro GABA-transaminase inhibitory compounds from the root of Angelica dahurica. Phytother Res, 2005, 19, 839-845.
7. Czuczwar SJ, Chodkowska A, Kleinrok Z, Małek U, Jagiełło-Wójtowicz E: Effects of calcium channel inhibitors upon the efficacy of common antiepileptic drugs. Eur J Pharmacol, 1990, 176, 75-83.
8. De Falco FA, Bartiromo U, Majello L, Di Geronimo G, Mundo P: Calcium antagonist nimodipine in intractable epilepsy. Epilepsia, 1992, 33, 343-345.
9. De Sarro GB, Meldrum BS, Nistico G: Anticonvulsant effects of some calcium entry blockers in DBA/2 mice. Br J Pharmacol, 1988, 93, 247-256.
10. 2+ influx and release. Eur J Pharmacol, 2007, 573, 170-175.
11. Heinemann U, Hamon B: Calcium and epileptogenesis. Exp Brain Res, 1986, 65, 1-10.
12. Jagiełło-Wójtowicz E, Czuczwar SJ, Chodkowska A, Szponar J, Kleinrok Z: Influence of calcium channel blockers on pentylenetetrazol and electroshock-induced convulsions in mice. Pol J Pharmacol Pharm, 1991, 43, 95-101.
13. Kamiński R, Jasiński M, Jagiełło-Wójtowicz E, Kleinrok Z, Czuczwar SJ: Effect of amlodipine upon the protective activity of antiepileptic drugs against maximal electroshock-induced seizures in mice. Pharmacol Res, 1999, 40, 319-325.
14. Kleiner HE, Vulimiri SV, Miller L, Johnson WH Jr, Whitman CP, DiGiovanni J: Oral administration of naturally occurring coumarins leads to altered phase I and II enzyme activities and reduced DNA adduct formation by polycyclic aromatic hydrocarbons in various tissues of SENCAR mice. Carcinogenesis, 2001, 22, 73-82.
15. Kułak W, Sobaniec W, Wojtal K, Czuczwar SJ: Calcium modulation in epilepsy. Pol J Pharmacol, 2004, 56, 29-41.
16. Litchfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther, 1949, 96, 99-113.
17. Löscher W, Fassbender CP, Nolting B: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res, 1991, 8, 79-94.
18. Löscher W, Nolting B: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Res, 1991, 9, 1-10.
19. Łuszczki JJ, Czuczwar SJ: Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis. Eur Neuropsychopharmacol, 2005, 15, 133-142.
20. G-nitro-L-arginine on the anticonvulsant and acute adverse effects of some newer antiepileptic drugs in the maximal electroshock-induced seizures and chimney test in mice. Pharmacol Rep, 2006, 58, 955-960.
21. Łuszczki JJ, Głowniak K, Czuczwar SJ: Imperatorin enhances the protective activity of conventional antiepileptic drugs against maximal electroshock-induced seizures in mice. Eur J Pharmacol, 2007, 574, 133-139.
22. Łuszczki JJ, Głowniak K, Czuczwar SJ: Time-course and dose-response relationships of imperatorin in the mouse maximal electroshock seizure threshold model. Neurosci Res, 2007, 59, 18-22.
23. Łuszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ: Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch Pharmacol, 2006, 373, 169-181.
24. Łuszczki JJ, Trojnar MK, Trojnar MP, Kimber-Trojnar Z, Szostakiewicz B, Zadrozniak A, Borowicz KK, Czuczwar SJ: Effects of three calcium channel antagonists (amlodipine, diltiazem and verapamil) on the protective action of lamotrigine in the mouse maximal electroshock-induced seizure model. Pharmacol Rep, 2007, 59, 672-682.
25. Marinho MM, de Bruin VM, de Sousa FC, Aguiar LM, de Pinho RS, Viana GS: Inhibitory action of a calcium channel blocker (nimodipine) on seizures and brain damage induced by pilocarpine and lithium-pilocarpine in rats. Neurosci Lett, 1997, 235, 13-16.
26. Meyer FB, Anderson RE, Sundt TM Jr, Sharbrough FW: Selective central nervous system calcium channel blockers - a new class of anticonvulsant agents. Mayo Clin Proc, 1986, 61, 239-247.
27. 2+ antagonist. Epilepsia, 1987, 28, 409-414.
28. Nakane Y, Seino M, Yagi A, Kaji S, Yamauchi T: Effects of flunarizine therapy on intractable epilepsy. Arzneimittelforschung, 1989, 39, 793-798.
29. Okamoto T, Yoshida S, Kobayashi T, Okabe S: Inhibition of concanavalin A-induced mice hepatitis by coumarin derivatives. Jpn J Pharmacol, 2001, 85, 95-97.
30. Overweg J, Binnie CD, Meijer JW, Meinardi H, Nuijten ST, Schmaltz S, Wauquier A: Double-blind placebo-controlled trial of flunarizine as add-on therapy in epilepsy. Epilepsia, 1984, 25, 217-222.
31. Starreveld E, de Beukelaar F, Wilson AF, McLean DR, Findlay HP: Double-blind cross-over placebo controlled study of flunarizine in patients with therapy resistant epilepsy. Can J Neurol Sci, 1989, 16, 187-190.
32. Stefani A, Spadoni F, Bernardi G: Voltage-activated calcium channels: targets of antiepileptic drug therapy? Epilepsia, 1997, 38, 959-965.
33. Thomas J: The effect of nimodipine on picrotoxin-induced seizures. Brain Res Bull, 1990, 24, 11-15.
34. Wurpel JN, Iyer SN: Calcium channel blockers verapamil and nimodipine inhibit kindling in adult and immature rats. Epilepsia, 1994, 35, 443-449.